Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03548987 · ClinicalTrials.gov registry record · Phase 3
Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 902
- Enrollment target
NCT03548987 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 902 participants.
The verdict
NCT03548987, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 902 participants
- Enrollment target
Study Summary
This study will look at the change in participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the medicine, the participant will have talks with study staff about healthy food choices, how to be more physically active and what a participant can do to lose weight. The participant will get semaglutide for the first 20 weeks. Then the participant will get either semaglutide or "dummy" medicine - which treatment the participant gets after the 20 weeks is decided by chance. The participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study will last for about 1.5 years.
Interventions
- DRUG Placebo
- DRUG Semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 902 participants |
| Start Date | 2018-06-04 |
| Est. Completion | 2020-03-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03548987
The ClinicalTrials.gov registry entry for NCT03548987 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 902 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03548987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03548987 about?
NCT03548987 is a clinical study titled "Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity". This study will look at the change in participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the medicine, the participant will have talks w...
What is the current status of trial NCT03548987?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 902 participants. The study started on 2018-06-04. Estimated completion is 2020-03-20.
What interventions are being tested in trial NCT03548987?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT03548987?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.